| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -75.6 | -67.0 |
| EPS (diluted, $ a share) | $-0.96 | $-1.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CLDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Celldex Therapeutics, Inc.: key numbers
- Share price
- $28.59Close, Nov 16
- Market cap
- $2.25B
- Shares outstanding
- 78.55MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Celldex Therapeutics, Inc.
All →Celldex Therapeutics Financial Results
Celldex Therapeutics reported third quarter 2026 financial results and provided a corporate update on its barzolvolimab program. The company highlighted positive Phase 3 topline results in chronic spontaneous urticaria (CSU) and anticipates a BLA submission in 2027.
“Barzolvolimab has significant potential to address enormous populations of high unmet need and shift the treatment paradigm goal from symptom improvement to complete symptom resolution, which for patients means no itch, no hives, no swelling.”
Anthony Marucci, Co-founder, President and Chief Executive Officer
“This quarter we reported best-in-disease results from our two Phase 3 studies in CSU, demonstrating barzolvolimab’s unparalleled ability to deliver complete response to patients—including even in patient populations suffering with severe disease or severe angioedema or with omalizumab refractory disease.”
Anthony Marucci, Co-founder, President and Chief Executive Officer
Celldex Therapeutics Clinical Trial Data
Celldex reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria (CSU), meeting the primary and all key secondary endpoints. The data showed rapid and sustained efficacy through 24 weeks, including in patients refractory to omalizumab, with a favorable safety profile. The company plans to submit a Biologics License Application (BLA) to the FDA in 2027.
- Earnings call
- Sep 22, 2026, 8:00 AM ET
“The results from our two Phase 3 EMBARQ-CSU trials showed efficacy that is best-in-disease in CSU. We believe barzolvolimab is well-positioned to address large CSU populations of high unmet need—as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.”
Anthony Marucci, Co-Founder, President, and Chief Executive Officer at Celldex
“Barzolvolimab continued to show unprecedented complete response rates across the overall studies and demonstrated strong differentiation in patient populations underserved by existing therapies, including those with severe disease or angioedema, and those whose disease is refractory to omalizumab.”
Diane Young, MD, Senior Vice President and Chief Medical Officer of Celldex